Literature DB >> 33287199

Revisiting One of the Dreaded Outcomes of the Current Pandemic: Pulmonary Embolism in COVID-19.

Munish Sharma1, Salim Surani2.   

Abstract

Pulmonary embolism (PE) is a commonly encountered clinical entity in patients with coronavirus disease 2019 (COVID-19). Up to 1/3 of patients have been found to have PE in the setting of COVID-19. Given the novelty of the virus causing this pandemic, it has not been easy to address diagnostic and management issues in PE. Ongoing research and publications of the scientific literature have helped in dealing with COVID-19 lately and this applies to PE as well. In this article, we attempt to succinctly yet comprehensively discuss PE in patients with COVID-19 with a review of the prevailing literature.

Entities:  

Keywords:  COVID-19; DVT; SARS-CoV-2; anticoagulation; pandemic; pulmonary embolism; thromboembolic disorder; thrombolytic

Year:  2020        PMID: 33287199     DOI: 10.3390/medicina56120670

Source DB:  PubMed          Journal:  Medicina (Kaunas)        ISSN: 1010-660X            Impact factor:   2.430


  2 in total

Review 1.  Advanced Imaging Supports the Mechanistic Role of Autoimmunity and Plaque Rupture in COVID-19 Heart Involvement.

Authors:  Maria Elena Laino; Angela Ammirabile; Francesca Motta; Maria De Santis; Victor Savevski; Marco Francone; Arturo Chiti; Lorenzo Mannelli; Carlo Selmi; Lorenzo Monti
Journal:  Clin Rev Allergy Immunol       Date:  2022-01-28       Impact factor: 8.667

2.  Secondary Infections in Patients with COVID-19 Pneumonia Treated with Tocilizumab Compared to Those Not Treated with Tocilizumab: A Retrospective Study at a Tertiary Hospital in Kenya.

Authors:  Reena Shah; Jasmit Shah; Jaimini Gohil; Gunturu Revathi; Salim Surani
Journal:  Int J Gen Med       Date:  2022-03-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.